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ABSTRACT 
Nanotechnology is being a utilized in medicine for diagnosis, therapeutic drug delivery and for the development of treatment for many ailments 
and disorders specifically in the areas of drug delivery, as medical diagnostic tools, and as diseases cure agents. During the past decades, the 
biosynthesis of metal nanoparticles has received considerable attention due to the growing need to develop environmentally so ciable 
technologies in material synthesis. In this study, we investigated the anti-diabetic potential of Leucas aspera leaf extract in streptozotocin-
induced diabetic Wistar albino rats and, serum creatinine, blood urea, protein content, enzymatic antioxidant, and non-enzymatic antioxidant 
was estimated.  This study evidenced the efficacy of the anti-diabetic potential of Leucas aspera leaf extract in the in-vivo model. 
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INTRODUCTION 
Diabetes mellitus is an endocrinal disorder related to 
depleted insulin secretion, injured pancreatic cells with 
altered carbohydrate, lipid, and protein metabolism and 
moreover increased risk of complication of many diseases. 
According to the report generated by World health 
organization (WHO), in 2014 approximately 422 million 
adults were living with diabetes globally, in comparison to 
108 million in 1980. The worldwide occurrence of diabetes 
has almost doubled since 1980, increasing from 4.7 to 8.5% 
in the adult population. Over the past decade, diabetes 
incidence has increased faster in low and middle-income 
countries than in high-income countries1. According to the 
International Diabetes Federation, in 2013 around 50% of 
all people with diabetes live in just three countries: China 
consists 98.4 million, India having 65.1 million and the USA 
24.4 million.   
Therapy of diabetes includes long term use of oral 
hyperglycemic agents or insulin therapy and lifestyle 
modifications, dietary control and regular physical exercise2.  
In recent times it has been reported that phytotherapy is 
considered to be less toxic and with minimal or no side 
effects in comparison with allopathic medicines3.  Reports 
from ethnobotany suggested that about 800 medicinal plants 
possess an anti-diabetic potential and bioactive compounds4. 
Various botanical medicinal plants have been found 
significantly managing diabetes and among them, Leucas 
aspera is a significant one.  
In our earlier investigations evidenced that the biological 
approach of synthesis of Iron oxide nanoparticles using 
Leucas aspera leaf extract was an eco-friendly and cost-
effective alternative to conventional chemical and physical 
methods and would be suitable for developing large scale 
production5.  In further, to use this comfortable, economic 
and greener method for development and application of iron 
oxide nanoparticles in environmental and biomedical 
requirements; in this present in-vivo study, we evaluated the 
pharmacological studies, enzymatic and non-enzymatic tests 
and assessed anti-diabetic potential of Leucas aspera leaf 
extract in streptozotocin-induced diabetic Wistar albino rats 
to prove the effectiveness.
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MATERIALS AND METHODS 
In-vitro studies: 
An eco-friendly synthesis of iron oxide nanoparticles and 
characteristics of the obtained Fe3O4 nanoparticles were 
studied in detail in the earlier published methodology5 for 
Ultraviolet-visible spectroscopy (UV-Vis), Fourier Transform 
Infra-Red Spectroscopy (FTIR), Scanning Electron 
Microscope (SEM), Energy-dispersive X-ray spectroscopy 
(EDX), X-Ray Diffraction (XRD) and High-Performance 
Liquid Chromatography (HPLC). The synthesized Iron oxide 
nanoparticles were also utilized for the antibacterial activity 
and antioxidant studies6. 
In-vivo studies: 
Animals 
Wistar albino rats of either sex weighing between 150-200 
gm were used for this study. The animals were obtained 
from animal house, Nandha College of Pharmacy, Erode. On 
arrival, the animals were placed at random and allocated to 
treatment groups in polypropylene cages with paddy husk 
as bedding. Animals were housed at a temperature of 
24±2oC and relative humidity of 30 – 70 %. A 12:12 light: 
day cycle was followed. All animals were allowed to free 
access to water and fed with standard commercial pelleted 
rat chaw (M/s. Hindustan Lever Ltd, Mumbai). All the 
experimental procedures and protocols used in this study 
were reviewed by the Institutional Animal Ethics Committee 
(688/PO/Re/S/02/CPCSEA) and were in accordance with 
the Institutional ethical guidelines. 
Experimental Induction of Diabetes in Rats  
Diabetes was induced experimentally in 12 hours fasted rats 
by a single intraperitoneal injection of Streptozotocin 
(50mg/kg) dissolved in 0.1M of citrate buffer (pH 4.5), 
followed by intraperitoneal administration of Streptozotocin 
(120 mg/kg) after 15 minutes. Since STZ is capable of 
inducing fatal hypoglycemia due to the sudden marked 
release of insulin from the pancreas, the rats that had been 
administered STZ were provided after 6 hours with a 10% 
glucose solution orally for 24 hours continuously so as to 
prevent hypoglycemia. After 72 hours, rats with a blood 
glucose concentration above 200 mg/dl were considered to 
be diabetic and were used for further diabetic studies. 
Experimental Design 
After the successful induction of experimental diabetes, the 
rats were divided into five groups of each five rats. Group I 
(Control 0.1% CMC): Normal rats received 0.1 % Carboxy 
Methyl Cellulose Solution (1mg/kg) as through oral route. 
Group II (Diabetic Control): Rats with STZ - Streptozotocin-
induced diabetic that were left untreated. Group III 
(Reference Control): Rats with STZ - Streptozotocin-induced 
diabetic rat treated with Glibenclamide (5mg/kg). Group IV 
(Compound C 200): Rats with STZ - Streptozotocin-induced 
diabetic rat treated with test Compound 200mg/kg of Leucas 
aspera leaf extracted in hot water. Group V: (Compound C 
400): Rats with STZ - Streptozotocin-induced diabetic rat 
treated with test Compound 400mg/kg of Leucas aspera leaf 
extracted in hot water. All the test compounds and the 
reference drug Glibenclamide administered once daily for 14 
days through an oral route using gastric gavage tubes.
 
Blood was withdrawn from the tail vein on 0, 4th, 7th and 14th 
day of drug administration and glucose levels are measured 
using a glucometer. At the end of the experimental period, 
the rats were fasted overnight, anesthetized with 
Pentobarbitone sodium (60mg/kg, i.p) anesthesia and the 
blood was collected by a retro-orbital puncture in non-
heparinized tubes. To obtain serum, blood samples were 
placed at room temperature for 30 minutes and centrifuged 
at 3000 X g for 10 minutes and the supernatant was taken 
for the determination of Lipid profiles, Liver function (AST, 
ALT, ALP) and Kidney function test.   
Preparation of Homogenate 
The animals were sacrificed with excess pentobarbitone 
sodium and the liver was removed from the animal and kept 
in the 0.2M, pH 6.6, phosphate buffer. The liver was crushed 
and the obtained homogenate was subjected to 
centrifugation process and centrifuged at 3000 rpm for 10 
min. The obtained supernatant was used for enzymatic and 
non-enzymatic tests. Determination of non-enzymatic 
antioxidant estimation of reduced glutathione (GSH) was 
measured by the method7 described by Beutler et al., 1986.  
Determination of enzymatic anti-oxidants tests were studied 
as per the standard protocols such as Catalase (CAT)8, 
Superoxide dismutase (SOD)9, Glutathione reductase 
(GSSH)10, Peroxides (Px) activity11, Glutathione peroxidase 
(GPx) activity was measured by the method described by 
Paglia and Valentine12. Estimation of lipid hydroperoxides13 
and estimation of malondialdehyde (MDA) analysis for lipid 
peroxidation as evidenced by the formation of thiobarbituric 
acid reactive substances (TBARS) and hydroperoxides (HP) 
were measured by the method of Nieshus and Samuelsson13. 

 
Estimation of Serum Creatinine14 was studied and 
absorbance was read at 520 nm and concentration of serum 
creatinine in mg/dl was calculated. Similarly, Protein 
content of the tissue homogenate was assayed by the 
method of Lowry15 and absorbance was measured at 660 
nm. Protein content was expressed as µg/mg of protein. 
Estimation of Blood Urea16 test was studied up to 14 days 
and the absorbance was read at 540 nm and concentration 
of urea in mg/dl was calculated. 
Determination of serum Lipid Profile 
Serum lipid profiling was studied as per the standard 
protocols, the serum sample were subjected to lipid analysis, 
such as Total cholesterol (TC), Triglycerides (TG), high-
density lipoprotein, cholesterol (HDL), low-density 
lipoprotein (LDL) and very low-density lipoprotein 
cholesterol (VLDL).    
Statistical Analysis 
Results were represented as mean ± SEM. The data were 
analyzed by using one-way analysis of variance (ANOVA) 
followed by Dunnett’s‘t’ test using GraphPad version 3. P 
values < 0.05 were considered as significant.
 
RESULTS AND DISCUSSION 
Recent developments in nanotechnology have a led to the 
growth of novel nanomaterial, which ultimately increases 
possible health and environmental hazards. Attention in 
developing environmentally benign procedures for the 
synthesis of nanoparticles has been improved. The purpose 
is to minimize the negative impacts of synthetic procedures, 
their accompanying chemicals, and derivative compounds. 
The exploitation of different biomaterials for the synthesis of 
nanoparticles is considered a valuable approach in green 
nanotechnology6. 
For evidence, Iron oxide nanoparticles using leaf extract of 
Leucas aspera was investigated in detail in the earlier in-
vitro study. The characteristics of the obtained Fe3O4 
nanoparticles were studied using UV-Visible 
spectrophotometer, FTIR, SEM with EDX, XRD, and HPLC. 
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The synthesized Iron oxide nanoparticles were successfully 
exploited for the antibacterial activity and antioxidant 
studies5. To prove the efficacy of the anti-diabetic potential 
of Leucas aspera leaf extract in the in-vivo model, we 
evaluated the anti-diabetic potential of Leucas aspera leaf 
extract in Streptozotocin-induced diabetic Wistar albino rats 
to attest the potency and effectiveness. 
The effect of the test compound from leaf extracts of Leucas 
aspera was studied for its hypoglycemic effect against 
Streptozotocin-induced diabetic rats and the results are 
tabulated in Table 1. The induction of diabetes in rats was 
confirmed by the elevation of blood sugar levels after the 
administration of STZ more than 200 mg/dl.  Streptozotocin-
induced diabetic rat treated with Glibenclamide (5mg/kg) 
was used as reference control significantly reduced the 
blood sugar levels from the 4th day onwards and on the 14th 
day, the blood sugar was found to be 106.60± 8.43 mg/dl.   
The 200 mg of hot water extract of L. aspera leaf moderately 
decreased the blood sugar level 117.66±4.49 from 4th day 
onwards and the effect was maintained until the end of the 
treatment against the reference control (106.60± 8.43 
mg/dl).  The 400 mg/kg of hot water extract of L. aspera leaf 
showed (98.35±7.73) good hypoglycemic activity against 
STZ induced diabetes in rats. 
 
Table 1. Effect of test compounds on Blood Sugar Levels of STZ induced Diabetic in Rats 
Drug  
Treatment 
Mean Blood Sugar Level  (mg/dl) 
Before STZ  After STZ  0 Day 4th Day 7th Day 14th Day 
Control 
0.1% CMC 
103.66± 
6.65 
100.30± 
7.76 
104.54± 
7.33 
98.71± 
6.88 
97.54± 
6.92 
103.83± 
8.72 
Diabetic  
Control 
99.53± 
5.31 
223.59± 
9.35 
221.62± 
12.60 
229.34± 
9.52 
220.51± 
5.83 
227.58± 
8.34 
Reference  
Control 
103.16± 
7.41 
217.32± 
8.71 
210.44± 
11.96 
182.05± 
8.62** 
127.28± 
8.50*** 
106.60± 
8.43*** 
Compound C 
200 
91.50± 
6.30 
219.00± 
9.22 
209.30± 
4.62 
196.58± 
4.70 
164.20± 
5.07** 
117.66± 
4.49*** 
Compound C  
400 
115.71± 
5.90 
216.37± 
7.40 
211.00± 
6.35 
163.22± 
5.44** 
137.61± 
9.90*** 
98.35± 
7.73*** 
Values are in mean ± SEM (n=5), *P<0.05, **P<0.01, ***P<0.001 Vs Diabetic Control 
 
The effect of leaf extracts of Leucas aspera on serum sample 
were studied to lipid analysis and biochemical parameters 
like Total cholesterol (TC), Triglycerides (TG), High-Density 
Lipoprotein (HDL), Low-Density Lipoprotein (LDL) and Very 
Low-Density Lipoprotein (VLDL) were analyzed and the 
results are summarized and biochemical parameters 
analysis is tabulated in Table 2. 
The animals treated with STZ enhanced the total cholesterol 
compared to normal control. Glibenclamide (5 mg/kg) 
significantly (P<0.001) decreased the total cholesterol 
(163.24± 8.04) enhanced by STZ (124.40± 10.63).  The low 
dose (200 mg/kg) of hot water leaf extract of L. aspera 
showed less significant (P<0.05) decrease in cholesterol by 
141.65± 7.05 and the high dose (400 mg/kg) of hot water 
leaf extract of L. aspera showed more significant (P<0.01) 
decrease in cholesterol by 131.24± 6.82 as compared to 
diabetic control (163.24± 8.04).  
The animals treated with STZ enhanced the triglycerides 
compared to normal control. Glibenclamide (5 mg/kg) 
significantly (P<0.001) decreased the triglycerides (121.75± 
7.62) enhanced by STZ (69.27±5.88).  The low dose (200 
mg/kg) of hot waterleaf extract of L. aspera showed less 
significant (P<0.01) decrease in triglycerides by 84.65±4.52 
and the high dose (400 mg/kg) of hot water leaf L. aspera 
leaf extracts showed more significant (P<0.01) decrease in 
triglycerides by 77.74±6.30 as compared to diabetic control 
(121.75± 7.62). 
The animals treated with STZ enhanced HDL Cholesterol 
compared to normal control. Glibenclamide (5 mg/kg) 
significantly (P<0.001) decreased the HDL Cholesterol 
(21.54± 1.86) enhanced by STZ (38.65±2.54).  The low dose 
(200 mg/kg) of hot waterleaf extract of L. aspera showed 
less significant (P<0.05) decrease in HDL Cholesterol by 
25.53±1.44 and the high dose (400 mg/kg) of hot water leaf 
L. aspera leaf extracts showed more significant (P<0.001) 
decrease in HDL Cholesterol by 32.80±1.90 as compared to 
diabetic control (21.54± 1.86). 
The animals treated with STZ enhanced LDL Cholesterol 
compared to normal control. Glibenclamide (5 mg/kg) 
significantly (P<0.001) decreased the LDL Cholesterol 
(79.33± 6.24) enhanced by STZ (46.30±2.52).  The low dose 
(200 mg/kg) of hot waterleaf extract of L. aspera showed 
less significant (P<0.05) decrease in LDL Cholesterol by 
65.63±3.42 and the high dose (400 mg/kg) of hot water leaf 
L. aspera leaf extracts showed more significant (P<0.01) 
decrease in LDL Cholesterol by 55.43±2.11 as compared to 
diabetic control (79.33± 6.24). 
The animals treated with STZ enhanced VLDL Cholesterol 
compared to normal control. Glibenclamide (5 mg/kg) 
significantly (P<0.001) decreased the VLDL Cholesterol 
(34.40± 2.76) enhanced by STZ (18.39±1.12).  The low dose 
(200 mg/kg) of hot waterleaf extract of L. aspera showed 
less significant (P<0.05) decrease in VLDL Cholesterol by 
29.37±2.03 and the high dose (400 mg/kg) of hot water leaf 
L. aspera leaf extracts showed more significant (P<0.001) 
decrease in VLDL Cholesterol by 23.22±1.09 as compared to 
diabetic control (34.40± 2.76). 
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Table 2. Effect of test compounds on Lipid Levels of STZ induced Diabetic in rats 
Drug Treatment 
Lipid Profiles (mg/dl) 
Total Cholesterol Triglyceride 
HDL - 
Cholesterol 
LDL - 
Cholesterol 
VLDL 
Cholesterol 
Control 
0.1% CMC 
117.63± 
8.52 
65.21± 
3.64 
40.27± 
2.95 
41.34± 
2.55 
16.97± 
1.08 
Diabetic Control 
163.24± 
8.04 
121.75± 
7.62 
21.54± 
1.86 
79.33± 
6.24 
34.40± 
2.76 
Reference Control 
124.40± 
10.63** 
69.27± 
5.88*** 
38.65± 
2.54*** 
46.30± 
2.52*** 
18.39± 
1.12*** 
Compound C 200 
141.65± 
7.05* 
84.65± 
4.52** 
25.53± 
1.44* 
65.63± 
3.42* 
29.37± 
2.03* 
Compound C  400 
131.24± 
6.82** 
77.74± 
6.30** 
32.80± 
1.90*** 
55.43± 
2.11** 
23.22± 
1.09*** 
Values are in mean ± SEM (n=6), *P<0.05, **P<0.01, ***P<0.001 Vs Diabetic Control 
 
The effects of leaf extracts of L. aspera leaves on serum blood 
urea nitrogen (BUN) and creatinine in STZ induced diabetes 
in rats and the results were tabulated in table 3.  The Blood 
Urea Nitrogen and serum creatinine was increased in the STZ 
induced diabetes animals as compared to normal control 
animals. Hot water extract of L. aspera leaf at a dose of 200 
mg/kg showed less significant (P<0.001) decrease in blood 
urea nitrogen by 22.54± 1.65 and at 400 mg/kg dose of hot 
water extract of   L. aspera leaf more significant (P<0.001) 
decrease in blood urea nitrogen was observed as 20.58 ± 
1.44 as compared to diabetic control (39.63 ± 2.63). 
Similarly, hot water extract of L. aspera leaf at a dose of 200 
mg/kg showed less significant (P<0.001) decrease in 
creatinine by 0.77± 0.02 and at 400 mg/kg dose of hot water 
extract of   L. aspera leaf more significant (P<0.001) decrease 
in creatinine was observed as 0.69 ± 0.03 as compared to 
diabetic control (1.84 ± 0.01).  
 
 
Table 3. Effect of test compounds on Kidney functions of STZ induced Diabetic in rats 
Drug 
Treatment 
Kidney Function Test 
BUN 
(mg/dl) 
Creatinine 
(mg/dl) 
Control 
0.1% CMC 
17.35±0.96 0.48±0.02 
Diabetic Control 39.63±2.63 1.84±0.01 
Reference Control 19.66±1.04*** 0.63±0.03*** 
Compound C 200 22.54±1.65*** 0.77±0.02*** 
Compound C  400 20.58±1.44*** 0.69±0.03*** 
Values are in mean ± SEM (n=6), *P<0.05, **P<0.01, ***P<0.001 Vs Diabetic Control 
 
The effects of leaf extracts of L. aspera leaves on MDA and LH 
in STZ induced diabetes in rats and the results were 
tabulated in table 4. The MDA and LH were increased in the 
STZ induced diabetes animals as compared to normal control 
animals. Hot water extract of L. aspera leaf at a dose of 200 
mg/kg showed a decrease in MDA by 1.28± 0.03 and at 400 
mg/kg dose of hot water extract of L. aspera leaf more 
significant (P<0.05) decrease in MDA was observed as 1.02 ± 
0.04 as compared to diabetic control (1.32 ± 0.02). Similarly, 
hot water extract of L. aspera leaf at a dose of 200 mg/kg 
showed less significant (P<0.01) decrease in LH by 1.01± 
0.04 and at 400 mg/kg dose of hot water extract of L. aspera 
leaf more significant (P<0.05) decrease in LH was observed 
as 0.94 ± 0.05 as compared to diabetic control (1.08 ± 0.02). 
  
Table 4. Effect of test compounds on liver MDA and LH in control and experimental animals 
 
Drug Treatment 
 
MDA 
(nmoles/min/mg protein) 
LH 
(nmoles/min/mg protein) 
Control 
0.1% CMC 
0.78±0.03 0.64±0.04 
Diabetic Control 1.32±0.02a 1.08±0.02a 
Reference Control 0.99±0.01b 0.87±0.01b 
Compound C 200 1.28±0.03 1.01±0.04b 
Compound C  400 1.02±0.04c 0.94±0.05c 
Values are mean ± SEM; n=6 in each group; aP <0.01 when compared to normal control; bP<0.01, cP<0.05,   when compared to 
diabetic control (one-way ANOVA followed by Dunnett’s ‘t’ test). 
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The effects of leaf extracts of L. aspera leaves on liver 
enzymatic antioxidants in STZ induced diabetes in rats and 
the results were tabulated in table 5. The Catalase (CAT), 
Superoxide dismutase (SOD), Glutathione reductase (GSSH), 
Peroxides (Px) activity, Glutathione peroxidase (GPx) 
activity results were observed that effect was increased in 
the STZ induced diabetes animals as compared to normal 
control animals. Similarly, the effects of leaf extracts of L. 
aspera leaves on liver non-enzymatic antioxidants in STZ 
induced diabetes in rats and the results were tabulated in 
table 6. The reduced glutathione (GSH), Vitamin C and 
Vitamin E results were observed that effect was also 
increased in the STZ induced diabetes animals as compared 
to normal control animals.  
 
Table 5. Effect of test compounds on liver enzymatic antioxidants in control and experimental animals 
Values are mean ± SEM; n=6 in each group; aP <0.01 when compared to normal control; bP<0.01, cP<0.05,   when compared to 
diabetic control (one-way ANOVA followed by Dunnett’s ‘t’ test). 
 
Table 6. Effect of test compounds on liver non-enzymatic antioxidants in control and experimental animals
 
 
Drug Treatment 
 
GSH 
(nmoles/min/mg protein) 
Vitamin C 
μgm/mg protein 
Vitamin E 
μgm/mg protein 
Control 
0.1% CMC 
12.4±0.9 4.8±0.03 7.1±0.02 
Diabetic Control 9.6±0.8a 3.4±0.02a 5.8±0.03a 
Reference Control 11.8±0.7b 4.5±0.04b 6.9±0.02b 
Compound C 200 10.2±0.5b 3.3±0.03 5.9±0.03 
Compound C  400 10.8±0.6b 3.9±0.02b 6.5±0.04b 
Values are mean ± SEM; n=6 in each group; aP <0.01 when compared to normal control; bP<0.01, cP<0.05, when compared to 
diabetic control (one-way ANOVA followed by Dunnett’s ‘t’ test). 
 
Thus collectively, the current study examined the pattern of 
diabetes induced by chemical agent Streptozotocin and oral 
glucose loading in experimental rats, and their responses to 
anti-diabetic agents in order to deduce the suitability or 
otherwise of chemical induction as a model for studying 
diabetes mellitus in experimental animals was investigated 
positively. 
CONCLUSION: 
Though different types of oral hypoglycemic agents are 
available along with insulin for the treatment of diabetes 
mellitus, there is a growing interest in herbal remedies, due 
to the side effects associated with these therapeutic agents. A 
need is felt to find alternative drugs, which are highly 
effective at non-toxic doses, inexpensive and accessible to 
the public. This can be achieved by screening newer 
molecules or plant products, which may be effective at non-
toxic dose levels.  In the Siddha and Ayurveda system of 
treatment, dry powder or crude extracts of plants are used to 
treat various disorders including cancer. The observed effect 
is attributed to may be a single compound or combination of 
compound present in the crude extracts. Because of 
perceived effectiveness, minimal side effects in clinical 
experience and relatively low cost, herbal drugs are widely 
prescribed even when their biologically active compounds 
are unknown. Our study proved in such a way by in-vitro and 
in-vivo to explore subsequent free radical scavenging and 
anti-diabetic effect of the traditionally used plant, Leucas 
aspera. This present study thus will become a milestone in 
developing a new drug from unexplored plant leaves, Leucas 
aspera for utilization of the human population in an effective 
manner for the control of the diabetes mellitus.
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